key: cord-0758623-m67acbzd
authors: Kang, Chang Kyung; Han, Gi-Chan; Kim, Minji; Kim, Gwanghun; Shin, Hyun Mu; Song, Kyoung-Ho; Choe, Pyoeng Gyun; Park, Wan Beom; Kim, Eu Suk; Kim, Hong Bin; Kim, Nam-Joong; Kim, Hang-Rae; Oh, Myoung-don
title: Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity
date: 2020-05-31
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.05.106
sha: ebc9df3be57a45625c703a3451bc86ee32e13382
doc_id: 758623
cord_uid: m67acbzd

Abstract Objectives We hypothesized that immune response may contribute to progression of coronavirus disease-19 (COVID-19) at the second week of illness. Therefore, we compared cell-mediated immune (CMI) responses between severe and mild COVID-19 cases. Methods We examined peripheral blood mononuclear cells of laboratory-confirmed COVID-19 patients from their first and third weeks of illness. Severe pneumonia was defined as an oxygen saturation ≤ 93% at room air. Expressions of molecules related to T-cell activation and functions were analyzed by flow cytometry. Results The population dynamics of T cells at the first week were not different between the two groups. However, total numbers of CD4+ and CD8 + T cells tended to be lower in the severe group at the third week of illness. Expressions of Ki-67, PD-1, perforin, and granzyme B in CD4+ or CD8+ T cells were significantly higher in the severe group than in the mild group at the third week. In contrast to the mild group, the levels of their expression did not decrease in severe group. Conclusions Severe COVID-19 had higher degree of proliferation, activation, and cytotoxicity of T-cells at the late phase of illness without cytotoxic T-cell contraction, which might contribute to the development of severe COVID-19.

4 accelerate the development of therapeutic strategies.

Recent viral shedding kinetics study showed that virus titers usually reach peak during the first week of illness, and decline during the second week of illness , Zou et al., 2020 . It is of note that patients with COVID-19 pneumonia may suddenly deteriorate 7-10 days after illness onset, resulting in intensive care unit admission , Zhou et al., 2020 . Therefore, we hypothesized that the immune response may play an important role for this discrepant clinical deterioration in COVID-19 patients. In this study, we aimed to compare CMI responses between severe and mild COVID-19 patients at their first and third week of illness.

We analyzed peripheral blood mononuclear cells (PBMCs) of laboratory-confirmed COVID-19 patients who had been treated at Seoul National University Hospital and Seoul National University Bundang Hospital. We collected peripheral bloods of the patients at the first and third week of illness. A severe case was defined as having radiological pneumonia and having an oxygen saturation of 93% or less at room air whenever during illness, while others were classified as a mild case (Wu and McGoogan, 2020) . We also analyzed healthy volunteers' PBMCs to accurately assess COVID-19-related CMI responses. Institutional Review Boards of Seoul National University Hospital and Seoul National University Bundang Hospital approved the study (IRB No. 2003 -011-1105 and B-2004 , and waived the need for written informed consent of COVID-19 patients on public health grounds.

PBMCs were purified from heparinized peripheral blood using a Ficoll-Histopaque gradient (1.077 g/mL; GE Healthcare Life Sciences, Piscataway, NJ, USA) (Kim et al., 2006) . The J o u r n a l P r e -p r o o f PBMCs were then stored in liquid nitrogen after the addition of 50% fetal bovine serum (FBS), 10% dimethyl sulfoxide, and 40% RPMI-1640 (Life Technologies, Carlsbad, CA, USA) until assayed (Cho et al., 2012) . Cryopreserved PBMCs were thawed and stained as following anti-human antibodies (Abs): V450-anti-HLA-DR, phycoerythrin (PE)-anti-CD25, fluorescein isothiocyanate (FITC)-anti-Ki-67, allophycocyanin-indotricarbocyanine (Cy7)anti-CD8, FITC-anti-perforin, Alexa Fluor ® 700-anti-granzyme B, Alexa Fluor ® 647-anti-FoxP3, FITC-anti-IL-2, PE-anti-IL-4 from BD Biosciences (San Jose, CA, USA); eFluor ® 450-anti-IL-7R, peridinin-chlorophyll proteins (PerCP)-cyanine 5.5 (Cy5.5)-anti-CD45RA, PE-Cy7-anti-interferon- (IFN-), eFluor ® 660-anti-IL-17 from eBioscience (San Diego, CA, USA); Brilliant Violet (BV) 605-anti-CD4, Alexa Fluor ® 700-anti-PD-1, BV605-anti-CD4, BV21-anti-CD8 from BioLegend (San Diego, CA, USA). FACS staining was performed as described previously (Cho et al., 2012 , Kim et al., 2006 . A fluorescence minus one (FMO) control, a tube of cells stained with all fluorochromes used in the experiment except one, was used to determine the cut-off point between the background fluorescence and the positive population in this experiment.

For staining the effector molecules and the proliferation marker, cells fixed with 2% paraformaldehyde and permeabilized with BD Perm/Wash™ buffer (BD Biosciences). Next, the cells were stained with fluorescently labeled Abs for perforin, granzyme B, Ki-67, or surface molecules.

To stain intracellular cytokines, cells were resuspended in RPMI 1640 medium containing 10% FBS and 1% penicillin/streptomycin (all reagents from Life Technologies), incubated for 30 min at 37°C, and then stimulated for 4 h at 37°C with phorbol 12-myristate 13-acetate (PMA; 50 ng/mL) and ionomycin (1 μg/mL) (both reagents from Sigma-Aldrich, St. Louis, MO, USA) in the presence of Golgistop ® (BD Biosciences).

After stained with the appropriate Abs, the cells were analyzed on a BD LSRFortessa™ J o u r n a l P r e -p r o o f (BD Biosciences) instrument with FACSDiva™ software, and data were analyzed using FlowJo ® software (TreeStar, Ashland, OR, USA).

All laboratory data are expressed as the mean ± standard error of the mean (SEM). Data were compared using the two-tailed Mann-Whitney U test or Wilcoxon signed rank test. In all analyses, P < 0.05 was considered to indicate statistical significance. All analyses were performed using PASW for Windows (version 25.0; SPSS Inc., Chicago, IL, USA) and all graphs were plotted using GraphPad Prism 6.01 (GraphPad Software, La Jolla, CA, USA).

Four severe and eight mild cases were included in this study. Median (range) ages in severe and mild groups were 62 (35-82) and 55 (25-79), respectively (P = 0.552). Male proportions were 50.0% (2/4) and 25.0% (2/8) in these groups (P = 0.547). All of them had no prior signs of immunodeficiency. PBMCs of one severe patient were available only at his third week of illness. Clinical and laboratory characteristics when the first-and third-week samples were collected are summarized in Table 1 . PBMCs from five healthy volunteers were also analyzed. Their median (range) age was 35 (28-47), and three of them (60%) were male. Their results are described in Table 2 and shown in Figures as gray boxes to indicate their interquartile range.

In general, neutropenia or lymphopenia can occur during the early stages of respiratory viral infection (Cheng et al., 2019 , Colamussi et al., 1999 . Thus, to confirm how they change in COVID-19 patients, we analyzed the changes in leukocyte subpopulations at the first week and third week of illness. The absolute numbers (cells/μL) of lymphocytes were comparable between the severe and mild groups in both time points, although they were lower than that from healthy controls (Table 2 and Figure 1A ). Although CD4 + and CD8 + T cell counts tended to be lower in the severe group than in the mild group at the third week of illness (mean ± standard error of the mean [SEM]; CD4 + T cell, 396.5 ± 101.9 in the severe group vs. 684.3 ± 82.0 in the mild group, P = 0.062; CD8 + T cell, 250.9 ± 50.1 in the severe group vs. 445.0 ± 76.1 in the mild group, P = 0.174, Figure 1B) , there was no difference at the first week ( Table 2) . This raises the question of whether there are significant changes in immunecell subsets according to different clinical course.

To investigate dynamics of the antigen-specific T cells according to severity of COVID-19, we determined the frequency of proliferating or activated T cells in the two groups. Although we could not attempt staining with peptide-MHC tetramer (Altman et al., 1996) for SARS-CoV-2, it was thought that analysis of these markers would sufficiently tracing antigen-J o u r n a l P r e -p r o o f specific T cells as previously known (Ndhlovu et al., 2015 , Soares et al., 2010 . Although frequencies (%) of Ki-67 + CD4 + and CD8 + T cells were higher than those from healthy control in both groups, they were significantly higher in the severe group than in the mild group (mean ± SEM, the severe group vs. the mild group; Ki-67 + in CD4 + T cells, 6.7 ± 1.9

vs. 2.4 ± 0.3, P = 0.011; Ki-67 + in CD8 + T cells, 10.9 ± 1.8 vs. 4.3 ± 1.1, P = 0.027; Figure   1C and 1D), signifying higher rate of T-cell turnover in the severe group.

We also examined frequencies (%) of HLA-DR, PD-1, and CD38 as makers of activated T cells. Although they tended to be higher in both group than in healthy control group, there were no differences at the first week between two groups ( Table 2) . However, activated T cells tended to be higher in the severe group than in the mild group at the third week, especially in terms of PD-1 expression (mean ± SEM, the severe group vs. the mild group;

HLA-DR + in CD4 + T cell, 4.3 ± 1.9 vs. 2.4 ± 0.4, P = 0.396; HLA-DR + in CD8 + T cells, 3.8 ± 0.9 vs. 3.7 ± 1.9, P = 0.174; PD-1 + in CD4 + T cells, 2.3 ± 0.8 vs. 0.4 ± 0.1, P = 0.007; PD-1 + in CD8 + T cells, 1.4 ± 0.2 vs. 0.6 ± 0.3, P = 0.042; CD38 + in CD4 + T cells, 0.7 ± 0.6 vs. 0.3 ± 0.2, P = 0.234; CD38 + in CD8 + T cells, 3.0 ± 1.5 vs. 1.7 ± 0.9, P = 0.234; Figure 2A ). Taken together, severe group showed higher degree of proliferation and activation of T cells.

Given the fact that regulatory T cells (Tregs), FoxP3 + CD4 + T cells, suppress activation, proliferation and cytokine production of CD4 + and CD8 + T cells (Sakaguchi, 2004) , it was raised the possibility whether excessive T-cell activation in the severe group could be due to a decrease in the number of Tregs or due to a decrease in inhibitory capacity. To address this, we measured frequency of FoxP3 + CD4 + Tregs. As a result, although statistically not significant, frequencies (%) of FoxP3 + CD4 + Tregs tended to be lower in severe patients at third week of illness (mean ± SEM, 5.9 ± 0.6 in the severe group vs. 7.4 ± 0.9 in the mild group, P = 0.131, Figure 2B) , suggesting that the overall inhibitory capacity for effector T cells would be reduced.

Furthermore, we examined the expression levels of effector molecules which could eradicate infected cells as well as cause tissue damage (Cho et al., 2012 , Kim et al., 2012 , Kim and Shin, 2019 . Thus, we examined the expression of effector granules and cytokines to reveal the consequences of increased T-cell activation at the third week of illness. Frequencies (%) of perforin and granzyme B expression in both CD4 + and CD8 + T cells were higher in the severe group than in the mild group (mean ± SEM, the severe group vs. the mild group; perforin + in CD4 + T cells, 7.0 ± 2.2 vs. 2.3 ± 1.2, P = 0.038; granzyme B + in CD4 + T cells, 9.0 ± 3.0 vs. 6.2 ± 1.9, P = 0.571; perforin + in CD8 + T cells, 47.6 ± 1.4 vs. 26.5 ± 4.8, P = 0.008; granzyme B + in CD8 + T cells, 68.1 ± 7.4 vs. 40.0 ± 5.8, P = 0.008; Figure 3A ). Proportions (%) of IL-7Rα low effector memory (CCR7 -CD45RA +/-) CD8 + T cells, which are known for high perforin and granzyme B expression (Kim et al., 2012) (Figure 3A , lower panel), were significantly higher in the severe group than in the mild group (mean ± SEM, 78.5 ± 3.9 in the severe group vs. 62.8 ± 3.1 in the mild group, P = 0.023; Figure 3B) , implying a higher cytotoxic potential in the severe groups at the third week of illness. Similarly, increased IL-7Rα low effector memory CD8 + T cells might be secondary to the expansion of effector memory CD8 + T cells (Supplementary Figure S1) , which is known to be produced by prolonged antigenic stimulation (Kim et al., 2006) . Compared to the difference in cytotoxic molecules, expression levels of IFN-, IL-2, IL-4, and IL-17 were comparable between the two groups at both time points (Table 2 and Figure 3C ). It is presumed that the effector cytokine expression alone did not significantly affect severity of COVID-19.

J o u r n a l P r e -p r o o f Interestingly, when compared the above immune responses between the first and third weeks of illness in each group, the mild group tended to show substantial reduction of Ki-67, PD-1, perforin, and granzyme B expressions compared to those in the severe group (Figure 4) . In contrast, the expression levels of those molecules in the severe group did not decrease or even tended to increase at the third week. Proportion of IL-7Rα low effector memory CD8 + T cells was not reduced in the severe group. Since cells expressing such markers are believed to represent cells that have recently been stimulated with antigen (Kim et al., 2007b , Ndhlovu et al., 2015 , Soares et al., 2010 , these findings imply a lack of cytotoxic T-cell contraction or delayed hyperactivation of T cells in the severe group.

Therapeutic strategies for severe COVID-19 should be developed in a timely manner, and understanding of its immunopathogenesis must be preceded. In this study, we observed higher turnover and activation of T cells and higher expression of cytotoxic effectors such as perforin and granzyme B in the severe group than in the mild group at the third week of illness. It might be due to the lack of cytotoxic T-cell contraction, and it is possible that such an immune response contributed to clinical deterioration at the second or third week of illness in severe COVID-19 patients.

Median days from symptom onset to dyspnea, development of acute respiratory distress syndrome, and ICU admission in COVID-19 patients were 7, 12, and 12 days, respectively , Zhou et al., 2020 . Interestingly, viral load of SARS-coronavirus-2 (SARS-CoV-2) peaks during the first 3-5 day of illness and declines thereafter , Zou et al., 2020 . Although initial viral loads are higher in severe cases, it also declines after the early peak . This viral shedding kinetics of COVID-19 is markedly different from that of MERS, which peaked during the second week of illness (Oh et al., 2016) . Such a time lag between the peak of viral load and the clinical deterioration implies J o u r n a l P r e -p r o o f the importance of immune response in the pathogenesis of severe COVID-19. And persistent or delayed hyperactivation of cytotoxicity could be explained in CD8 + T cells as well as CD4 + T cells (Juno et al., 2017) . Although there is no difference in the expression of cytokines between the severe and the mild groups, if IFN-γ-producing CD8 + T (Tc1) cells express highly cytotoxic molecules such as perforin and granzyme B, they may exhibit high cytotoxicity in the severe group.

There were a few studies explored CMI response in COVID-19 (Qin et al., 2020 , Thevarajan et al., 2020 . Although they reported activation of CD4 + and CD8 + T cells, decreased numbers of T cells, or high concentrations of cytotoxic granules, and some are consistent with the results of the present study, data on severe COVID-19 patients or temporal changes of CMI response were lack (Qin et al., 2020 , Thevarajan et al., 2020 . We believe that our results, focusing on immune responses characterizing severe COVID-19 cases with a temporal consideration, may elucidate the pathogenesis of severe COVID-19.

In addition, unknown factors that may affect the immune response could be related to severe COVID-19. In this regard, Cornberg et al. suggested an important possibility that the degree of antigen exposure can regulate the balance between protective immunity and immunopathology by presenting the medium-dose virus-induced immunopathology and Tcell exhaustion by massive virus exposure (Cornberg et al., 2013) . It seems consistent with the development of severe COVID-19 which clinically deteriorates when viral loads are declining. In addition, activated bystander CD8 + T cells induced by IL-15 can participate in protective immunity (Kim et al., 2007a , Sim et al., 2017 , but they also can cause excessive tissue damage because of its lack of specificity for the pathogen (Kim and Shin, 2019) . In this regard, an increase in IL-7R low effector memory CD8 + T cells, which are known to express activating receptor of natural killer cells and have cytotoxic ability through this receptor (Cho There are several therapeutic agents for the treatment of COVID-19. When considering the viral shedding kinetics , Zou et al., 2020 , antiviral agents such as lopinavir/ritonavir, remdesivir, or hydroxychloroquine , Yao et al., 2020 , may be effective during the first week of illness when the virus are actively replicating. In contrast, our study suggest that immune-modulating agents may be effective during the second week of illness.

This study has some limitations. First, numbers of patients analyzed in this study was small. Although we could find out important differences of CMI responses in severe and mild COVID-19 cases which were consistent with clinical course, it would be better to be verified in a larger cohort. Second, it would be desirable if there were more time points to be examined to elucidate the exact temporal changes of such responses or when the persistent cytotoxic T-cell activity returns to normal in severe cases. Finally, the potential immunomodulatory effects of lopinavir/ritonavir could not be adjusted because the drug was prescribed to all severe patients in this study.

We observed higher degree of proliferation, activation, and cytotoxicity of T-cells, accompanying with the lack of cytotoxic T-cell contraction in severe COVID-19 cases than in mild cases, which may contribute to the progression of pneumonia during the second week of illness. 

Phenotypic analysis of antigen-specific T lymphocytes

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Dynamic changes of lymphocyte counts in adult patients with severe pandemic H1N1 influenza A

Phenotypic characterization of peripheral T cells and their dynamics in scrub typhus patients

Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria

Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8 T cell response

Cytotoxic CD4 T Cells-Friend or Foe during Viral Infection?

Altered IL-7Ralpha expression with aging and the Front Immunol

Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Novel Coronavirus (2019-nCoV) situation reports

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Clinical course and risk factors for mortality the severity. (A) Perforin or granzyme B expressions in severe (n = 4, open circle) and mild cases (n = 8, closed circle) and representative dot plots showing the identification of perforin + , granzyme B + , IL-7Rα high , or IL-7Rα low cells in CD4 + or CD8 + T cells in severe (upper panels) or mild (lower panels) cases. (B) Frequencies of IL

IL-4, and IL-17 expressions in CD4 + and CD8 + T cells and representative dot plots showing the identification of IFN-γ + , IL-2 + , IL-4 + , and IL-17 + cells in CD4 + or CD8 + T cells in severe (upper panels) or mild (lower panels) cases. Bars denote mean values